[ Main Page | Editorial Board | About | Instructions ]
[ Table of Contents | Archive | Archive Search | Online Submission | Sponsor | E-mail ]

Turkish Journal of Cancer
1997, Volume 27, Number 1, Page(s) 19-26
[ Summary ]
High-dose therapy and autologous peripheral blood stem cell transplantation in patients with relapsed lymphoma
FİKRET ARPACI1, AHMET ÖZET1, MURAT BEYZADEOĞLU2, ŞEREF KÖMÜRCÜ1, BEKİR ÖZTÜRK1, ONUR HAMZAOĞLU3, ALPER ÖZKAN1, YÜCEL PAK2, ATİLLA YALÇIN4
Departments of 1Oncology, 2Radiation Oncology, 3Epidemiology and 4Hematology, Gülhane Military Medical Academy, Ankara-Turkey

Twenty lymphoma patients (14 Hodgkin’s Disease, 6 agressive non-Hodgkin’s lymphoma), treated with high-dose therapy or chemotherapy+radiotherapy, underwent peripheral blood stem cell transplantation between March 1993 and November 1996. Stem cells were mobilized by granulocyte-colony stimulating factor or granulocyte macrophage colony stimulating factor. The mean number of mononuclear cells per kg body weight collected from each patient was 7.10x108 (range: 2.2x108-10.21x108). Mean CD34+ cell number was 9.3xl06/kg (range: 2.03x108-14x108). Leucocyte and platelet engraftments occurred on mean 15th (range: 9-27) and 24th (range: 11-34) days, respectively, in one case, engraftment has not sufficiently developed within six months. Secondary engraftment failure was not observed. There were 5 early deaths in the posttransplant period (25%) and the mortality rate due to the infections was 15% (3/20). Two of 5 early deaths were due to CNS hemorrhage (5%) and drug toxicity (5%). Twelve patients are currently disease-free and 3 patients relapsed in the posttransplant period. Median survival time was 39.5 months. The overall survival for 40 months was 31.4% and four patients are still alive over 22 months.

[ Summary ]
Turkish Journal of Cancer web sitesi Novartis Onkoloji'nin karşılıksız eğitim katkılarıyla hazırlanmıştır.
[ Main Page | Editorial Board | About | Instructions ]
[ Table of Contents | Archive | Archive Search | Online Submission | E-mail ]